PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, NV 89169
September 27, 2023
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|Attention:||Doris Stacey Gama and Joe McCann|
|Re:||PharmaCyte Biotech, Inc.|
|Registration Statement on Form S-3|
|Filed September 12, 2023|
|File No. 333-272569 (the “Registration Statement”)|
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, PharmaCyte Biotech, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, September 29, 2023, at 4:01 p.m., Eastern Time, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request.
|Very truly yours,|
|PHARMACYTE BIOTECH, INC.|
|/s/ Joshua N. Silverman|
|Joshua N. Silverman|
|Interim Chief Executive Officer and Interim President|
cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
|Kenneth R. Koch, Esq.|
|Daniel A. Bagliebter, Esq.|